NasdaqGS:ZBIOBiotechs
How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors
Zenas BioPharma recently dosed the first subject in a Phase 1 trial of ZB021, an oral IL-17AA/AF inhibitor being evaluated for safety, tolerability, and pharmacokinetics in healthy volunteers in China, with early data expected by year-end 2026.
This first-in-human study underscores ZB021’s potential as a differentiated oral alternative to injectable IL-17 biologics for autoimmune and inflammatory diseases, supported by preclinical data showing anti-inflammatory activity and favorable ADME...